{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:04Z","timestamp":1789749484511,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05560-1","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:02:10Z","timestamp":1710500530000},"page":"2227-2237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-621X","authenticated-orcid":false,"given":"Aydan","family":"K\u00f6ken Av\u015far","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-0591","authenticated-orcid":false,"given":"Tuba","family":"Demirci Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-4180","authenticated-orcid":false,"given":"\u0130smail","family":"Sar\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"4","key":"5560_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cpm.2021.06.002","volume":"38","author":"M Barbe","year":"2021","unstructured":"Barbe M, Batra A, Golding S, Hammond O, Higgins JC, O\u2019Connor A, Vlahovic TC (2021) Pyoderma gangrenosum: a literature review. Clin Podiatr Med Surg 38(4):577\u2013588. https:\/\/doi.org\/10.1016\/j.cpm.2021.06.002","journal-title":"Clin Podiatr Med Surg"},{"issue":"5","key":"5560_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","volume":"23","author":"CA Maronese","year":"2022","unstructured":"Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV (2022) Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol 23(5):615\u2013634. https:\/\/doi.org\/10.1007\/s40257-022-00699-8","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"5560_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/exd.14534","volume":"31","author":"A Flora","year":"2022","unstructured":"Flora A, Kozera E, Frew JW (2022) Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease. Exp Dermatol 31(4):498\u2013515. https:\/\/doi.org\/10.1111\/exd.14534","journal-title":"Exp Dermatol"},{"issue":"3","key":"5560_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","volume":"19","author":"C George","year":"2019","unstructured":"George C, Deroide F, Rustin M (2019) Pyoderma gangrenosum\u2014a guide to diagnosis and management. Clin Med 19(3):224\u2013228. https:\/\/doi.org\/10.7861\/clinmedicine.19-3-224","journal-title":"Clin Med"},{"issue":"7","key":"5560_CR5","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/eji.201646680","volume":"47","author":"K Welsch","year":"2017","unstructured":"Welsch K, Holstein J, Laurence A, Ghoreschi K (2017) Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol 47(7):1096\u20131107. https:\/\/doi.org\/10.1002\/eji.201646680","journal-title":"Eur J Immunol"},{"issue":"11","key":"5560_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"5560_CR7","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.9646","volume":"103","author":"HS Kim","year":"2023","unstructured":"Kim HS, Kwon JE, Park YJ (2023) Atezolizumab plus bevacizumab-induced recalcitrant pyoderma gangrenosum treated with baricitinib: a case report. Acta Derm Venereol 103:adv9646. https:\/\/doi.org\/10.2340\/actadv.v103.9646","journal-title":"Acta Derm Venereol"},{"key":"5560_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100099","volume":"4","author":"M Scheinberg","year":"2021","unstructured":"Scheinberg M, Machado LA, Castro LGM, Ferreira SB, Michalany N (2021) Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun 4:100099. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100099","journal-title":"J Transl Autoimmun"},{"issue":"8","key":"5560_CR9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/ijd.16676","volume":"62","author":"LGM Castro","year":"2023","unstructured":"Castro LGM (2023) JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol 62(8):1088\u20131093. https:\/\/doi.org\/10.1111\/ijd.16676","journal-title":"Int J Dermatol"},{"key":"5560_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14810","author":"VA Sathyanarayana","year":"2023","unstructured":"Sathyanarayana VA, Roy D, Nagaraju B, Rao VKR (2023) Tofacitinib in pyoderma gangrenosum\u2014a case series. Int J Rheum Dis. https:\/\/doi.org\/10.1111\/1756-185X.14810","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"5560_CR11","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/ibd\/izz015","volume":"25","author":"MH Gregory","year":"2019","unstructured":"Gregory MH, Ciorba MA, Deepak P, Christophi GP (2019) Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab. Inflamm Bowel Dis 25(7):e87\u2013e88. https:\/\/doi.org\/10.1093\/ibd\/izz015","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"5560_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.17235\/reed.2021.7977\/2021","volume":"113","author":"P Salm\u00f3n Olavarr\u00eda","year":"2021","unstructured":"Salm\u00f3n Olavarr\u00eda P, Rubio Iturria S, Nantes Castillejo \u00d3 (2021) Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient. Rev Esp Enferm Dig 113(10):733\u2013734. https:\/\/doi.org\/10.17235\/reed.2021.7977\/2021","journal-title":"Rev Esp Enferm Dig"},{"issue":"5","key":"5560_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab005","volume":"27","author":"R Sedano","year":"2021","unstructured":"Sedano R, Jairath V (2021) Tofacitinib for the treatment of three immune-mediated conditions in one patient: ulcerative colitis, pyoderma gangrenosum, and alopecia areata. Inflamm Bowel Dis 27(5):e65. https:\/\/doi.org\/10.1093\/ibd\/izab005","journal-title":"Inflamm Bowel Dis"},{"key":"5560_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdcr.2023.05.016","volume":"37","author":"L Van Eycken","year":"2023","unstructured":"Van Eycken L, Dens AC, de Vlam K, Neerinckx B, De Haes P (2023) Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib. JAAD Case Rep 37:89\u201391. https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.016","journal-title":"JAAD Case Rep"},{"issue":"11","key":"5560_CR15","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1111\/ijd.16791","volume":"62","author":"MR Dos Santos","year":"2023","unstructured":"Dos Santos MR, Ianhez M, Ribeiro BN, de Queiroz BB, Miot HA (2023) Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. Comments on: \u201cJAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum.\u201d Int J Dermatol 62(11):e595\u2013e598. https:\/\/doi.org\/10.1111\/ijd.16791","journal-title":"Int J Dermatol"},{"issue":"4","key":"5560_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ddg.14716_g","volume":"20","author":"N Rahbar Kooybaran","year":"2022","unstructured":"Rahbar Kooybaran N, Korsten P, Sch\u00f6n MP, M\u00f6ssner R (2022) Ansprechen eines mit rheumatoider arthritis assoziierten pyoderma gangraenosum auf den JAK1-inhibitor upadacitinib. J Dtsch Dermatol Ges 20(4):522\u2013524. https:\/\/doi.org\/10.1111\/ddg.14716_g","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"5560_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.jfas.2013.07.003","volume":"52","author":"VK Shanmugam","year":"2013","unstructured":"Shanmugam VK, McNish S, Shara N, Hubley KJ, Kallakury B, Dunning DM, Attinger CE, Steinberg JS (2013) Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(\u00ae)). J Foot Ankle Surg 52(6):781\u2013785. https:\/\/doi.org\/10.1053\/j.jfas.2013.07.003","journal-title":"J Foot Ankle Surg"},{"issue":"2","key":"5560_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjd.16468","volume":"179","author":"S Nasifoglu","year":"2018","unstructured":"Nasifoglu S, Heinrich B, Welzel J (2018) Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol 179(2):504\u2013505. https:\/\/doi.org\/10.1111\/bjd.16468","journal-title":"Br J Dermatol"},{"issue":"9","key":"5560_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jdcr.2020.07.035","volume":"6","author":"AW Choi","year":"2020","unstructured":"Choi AW, Abuav R, Rabizadeh SM, Ansari R, Marsch AF (2020) Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral tofacitinib. JAAD Case Rep 6(9):939\u2013941. https:\/\/doi.org\/10.1016\/j.jdcr.2020.07.035","journal-title":"JAAD Case Rep"},{"issue":"5","key":"5560_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","volume":"17","author":"B Kochar","year":"2019","unstructured":"Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH (2019) Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol 17(5):991\u2013993. https:\/\/doi.org\/10.1016\/j.cgh.2018.10.047","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"5560_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/jvc2.62","volume":"1","author":"S Sitaru","year":"2022","unstructured":"Sitaru S, Biedermann T, Lauffer F (2022) Successful treatment of pyoderma gangrenosum with Janus kinase 1\/2 inhibition. JEADV Clin Pract 1(4):420\u2013423. https:\/\/doi.org\/10.1002\/jvc2.62","journal-title":"JEADV Clin Pract"},{"issue":"5","key":"5560_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s10067-023-06506-x","volume":"42","author":"K Bhowmick","year":"2023","unstructured":"Bhowmick K, Roongta R, Dey S, Dey S, Mondal S, Sinhamahapatra P, Ghosh P, Ghosh B (2023) Refractory Takayasu arteritis with recurrent pyoderma gangrenosum: a therapeutic challenge with case-based review. Clin Rheumatol 42(5):1469\u20131477. https:\/\/doi.org\/10.1007\/s10067-023-06506-x","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5560_CR23","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/ced.14683","volume":"46","author":"VE Orfaly","year":"2021","unstructured":"Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR (2021) Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol 46(6):1082\u20131085. https:\/\/doi.org\/10.1111\/ced.14683","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"5560_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/11595240-000000000-00000","volume":"13","author":"I Ahronowitz","year":"2012","unstructured":"Ahronowitz I, Harp J, Shinkai K (2012) Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 13(3):191\u2013211. https:\/\/doi.org\/10.2165\/11595240-000000000-00000","journal-title":"Am J Clin Dermatol"},{"key":"5560_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2958","volume":"350","author":"AD Ormerod","year":"2015","unstructured":"Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC, UK Dermatology Clinical Trials Network\u2019s STOP GAP Team (2015) Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350:h2958. https:\/\/doi.org\/10.1136\/bmj.h2958","journal-title":"BMJ"},{"issue":"4","key":"5560_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505\u2013509. https:\/\/doi.org\/10.1136\/gut.2005.074815","journal-title":"Gut"},{"issue":"14","key":"5560_CR27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","volume":"83","author":"J Dissemond","year":"2023","unstructured":"Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG (2023) Pyoderma gangrenosum: treatment options. Drugs 83(14):1255\u20131267. https:\/\/doi.org\/10.1007\/s40265-023-01931-3","journal-title":"Drugs"},{"issue":"2","key":"5560_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/iwj.13067","volume":"16","author":"H Ben Abdallah","year":"2019","unstructured":"Ben Abdallah H, Fogh K, Bech R (2019) Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J 16(2):511\u2013521. https:\/\/doi.org\/10.1111\/iwj.13067","journal-title":"Int Wound J"},{"issue":"4","key":"5560_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1159\/000519320","volume":"238","author":"H Ben Abdallah","year":"2022","unstructured":"Ben Abdallah H, Fogh K, Vestergaard C, Bech R (2022) Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review. Dermatology 238(4):785\u2013792. https:\/\/doi.org\/10.1159\/000519320","journal-title":"Dermatology"},{"issue":"3","key":"5560_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/1744666X.2018.1438269","volume":"14","author":"C Ahn","year":"2018","unstructured":"Ahn C, Negus D, Huang W (2018) Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 14(3):225\u2013233. https:\/\/doi.org\/10.1080\/1744666X.2018.1438269","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"5560_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164080","volume":"11","author":"AK Alves de Medeiros","year":"2016","unstructured":"Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J (2016) JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS ONE 11(10):e0164080. https:\/\/doi.org\/10.1371\/journal.pone.0164080","journal-title":"PLoS ONE"},{"key":"5560_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05418-y","author":"T Demirci Yildirim","year":"2023","unstructured":"Demirci Yildirim T, Kahraman A, K\u00f6ken Av\u015far A, Onen F, Akar S, Sari \u0130 (2023) Quantitative analysis of JAK\/STAT signaling pathway in patients of inflammatory skin disorders. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-023-05418-y","journal-title":"Rheumatol Int"},{"issue":"7","key":"5560_CR33","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253\u20131262. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210457","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05560-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T22:03:38Z","timestamp":1726178618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05560-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["5560"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05560-1","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"17 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient gave a written informed consent before written.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}